Section 16, Assisted Reproductive Technology (Regulation) Act, 2021 [S2A-R34]
As at 6 September 2026. In force from 12 May 2022 by S.O. 252(E) [N12-MJG].
16. Power to issue directions.—(1) The Licensing Authority may, by order in writing, direct any manufacturer to take such measures in relation to the manufacture of drugs as may be specified in the order, and such person shall comply with the direction within the period specified therein. (2) An order under sub-section (1) shall state the reasons on which it is made and shall be served on the person to whom it is addressed in such manner as may be prescribed.
Defined terms in this text (3)
drug: Section 2, Assisted Reproductive Technology (Regulation) Act, 2021 [S2AQNM] (In this Act, unless the context otherwise requires,—): "drug" includes all medicines for internal or external use of human beings or animals and all substances intended to be used for or in the diagnosis, treatment, mitigation or prevention of any disease or disorder in human beings or animals
drug: 19 more definitions.
Licensing Authority: Section 2, Assisted Reproductive Technology (Regulation) Act, 2021 [S2AQNM] (In this Act, unless the context otherwise requires,—): "Licensing Authority" means the authority appointed under section 4 to grant licences under this Act
Licensing Authority: 21 more definitions.
manufacture: Section 2, Assisted Reproductive Technology (Regulation) Act, 2021 [S2AQNM] (In this Act, unless the context otherwise requires,—): "manufacture" in relation to any drug, includes any process or part of a process for making, altering, ornamenting, finishing, packing, labelling, breaking up or otherwise treating or adopting any drug with a view to its sale or distribution
manufacture: 36 more definitions.
Made under this section, or naming it (0)
none
Cited by (0)
none
Not held (0)
none
Duties published under this section (0)
none